Claims for Patent: 7,928,132

Summary for Patent: 7,928,132

Title:	Methods for the amelioration of episodes of acute or chronic ulcerative colitis
Abstract:	Methods of ameliorating episodes of accute or chronic colitis are provided by using methimazole derivatives and tautomeric cyclic thiones in combination with another pharmaceutical compound.
Inventor(s):	Kohn; Leonard D. (Athens, OH), Goetz; Douglas J. (Athens, OH), Benavides-Peralta; Uruguaysito (Athens, OH), Gonzalez-Murguiondo; Mariana (Athens, OH), Harii; Norikazu (Yaminashi, JP), Lewis; Christopher J. (Athens, OH), Napolitano; Giorgio (Pescara, IT), Dagia; Nilesh D. (Athens, OH)
Assignee:	Ohio University (Athens, OH)
Application Number:	10/912,948
Patent Claims:	1. A method for the amelioration of episodes of acute or chronic ulcerative colitis in a mammal comprising administering to the mammal a pharmaceutical composition comprising an active compound having the formula selected from the group consisting of: ##STR00023## wherein Y is selected from the group consisting of H, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 substituted alkyl, --NO.sub.2, and the phenyl moiety: ##STR00024## and wherein no more than one Y group in said active compound is the phenyl moiety; R.sup.1 is selected from the group consisting of H, --OH, C.sub.1-C.sub.4 alkyl, and C.sub.1-C.sub.4 substituted alkyl; R.sup.2 is selected from the group consisting of H, C.sub.1-C.sub.4 alkyl and C.sub.1-C.sub.4 substituted alkyl; R.sup.4 is selected from the group consisting of H, C.sub.1-C.sub.4 alkyl, and C.sub.1-C.sub.4 substituted alkyl; X is selected from the group consisting of S and O; Z is selected from the group consisting of --SR.sup.3 and --OR.sup.3; and R.sup.3 is selected from the group consisting of H, C.sub.1-C.sub.4 alkyl, C.sub.1-C.sub.4 substituted alkyl, and --CH.sub.2Ph; and wherein at least two of the R.sup.2 and R.sup.3 groups in said compound are C.sub.1-C.sub.4 alkyl when neither Y is the phenyl moiety, in combination with at least one additional compound selected from the group consisting of salicylates, corticosteroids, immunosuppressants, antibiotics, anti adhesion molecules, and a vitamin D compound, wherein each substituted C.sub.1-C.sub.4 alkyl is a C.sub.1-C.sub.4 alkyl substituted with one or more of: hydroxyl groups, alkyoxyl groups, carboxyl groups, halogens, nitro groups, amino groups or acylamino groups. 2. The method of claim 1, wherein each substituted C.sub.1-C.sub.4 alkyl is a C.sub.1-C.sub.4 alkyl group substituted with groups selected from one or more of hydroxyl groups, alkyoxyl groups, and halogens. 3. The method according to claim 2, wherein the active compound is administered in conjunction with one or more drugs, agents or therapeutics selected from the group consisting of: glucocorticoids, 5-lipoxygenase inhibitors, .beta.-2 adrenoceptor agonists, muscarinic M1 and M3 antagonists, muscarinic M2 agonists, NK3 antagonists, LTB4 antagonists, cysteinyl leukotriene antagonists, bronchodilators, PDE4 inhibitors, PDE inhibitors, elastase inhibitors, MMP inhibitors, phospholipase A2 inhibitors, phospholipase D inhibitors, histamine H1 antagonists, histamine H-3 antagonists, dopamine agonists, adenosine A2 agonists, NK1 and NK2 antagonists, GABA-b agonists, nociceptin agonists, expectorants, mucolytic agents, decongestants, antioxidants, anti-IL-8 anti-bodies, anti-IL-5 antibodies, anti-IgE antibodies, anti-TNF antibodies, IL-10, adhesion molecule inhibitors, and growth hormones. 4. The method according to claim 2, wherein the pharmaceutical composition comprises from about 0.01% to about 25% of the active compound and from about 75% to about 99.99% of a pharmaceutically-acceptable carrier. 5. The method according to claim 1, wherein the active compound has the formula ##STR00025## 6. The method according to claim 1, wherein the active compound has the formula: ##STR00026## 7. The method according to claim 1, wherein the active compound has the formula: ##STR00027## 8. The method according to claim 1, wherein the active compound has the formula: ##STR00028## 9. The method according to claim 1, wherein Z is SR.sup.3 and one of the Y groups is the phenyl moiety. 10. The method according to claim 1, wherein R.sup.1 and R.sup.4 are H. 11. The method according to claim 1, wherein Z is SR.sup.3 and R.sup.3 is a methyl, and one of the Y groups is the phenyl moiety wherein R.sup.1 and R.sup.4 are H, and the R.sup.2 group is methyl. 12. The method according to claim 1, wherein one of the Y groups is the phenyl moiety, wherein R.sup.1 and R.sup.4 are H, and both R.sup.2 groups are methyl. 13. The method according to claim 1, wherein the active compound is: ##STR00029## 14. The method according to claim 1, wherein the active compound is: ##STR00030## 15. The method according to claim 1, wherein the active compound is: ##STR00031## 16. A method for the amelioration of episodes of acute or chronic ulcerative colitis in a mammal comprising administering to the mammal a pharmaceutical composition comprising an active compound having the formula selected from the group consisting of: ##STR00032## wherein R.sup.9 is selected from the group consisting of --OH, --M and --OOCCH.sub.2M; and wherein M is selected from the group consisting of F, Cl, Br and I. 17. A method for the amelioration of episodes of acute or chronic ulcerative colitis in a mammal comprising administering to the mammal a pharmaceutical composition comprising an active compound having the formula selected from the group consisting of: ##STR00033## wherein R.sup.10is selected from the group consisting of H, --NO.sub.2, Ph, 4-HOPh and 4-MPh; and wherein M is selected from the group consisting of F, Cl, Br and I.

Details for Patent 7,928,132

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Jubilant Hollisterstier Llc	N/A	positive skin test control-histamine	Injection	103891	03/13/1924		2040-01-28